DSM-Firmenich AG

DSFIR: XAMS (NLD)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|^>LOCK|v?^LOCK|CNGGL<>

DSM-Firmenich Earnings: Restructuring Noise Masks Strong Underlying Business

DSM-Firmenich reported 2% organic sales growth in the fourth quarter on a comparable basis, incorporating the announced divestment of its animal nutrition and health division. The company did not provide guidance for 2026, which contributed to an 8% share price decline on Feb. 12 amid uncertainty.

Sponsor Center